Latest Hotspot

Ractigen Therapeutics Gets NMPA Approval for Phase 1 Trials of RAG-17 in Chinese ALS Patients

24 May 2024
3 min read

Ractigen Therapeutics, a pharmaceutical company dedicated to the development of innovative treatments, has revealed that the Center for Drug Evaluation under Chinas National Medical Products Administration has given the green light to their Investigational New Drug application. This approval paves the way for the commencement of Phase 1 clinical trials in China for RAG-17, which is aimed at treating Amyotrophic Lateral Sclerosis.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The Phase I study initiating the IND is a randomized, double-blind, placebo-controlled trial assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of RAG-17 in ALS patients harboring the Superoxide Dismutase 1 (SOD1) mutation.

Dr. Long-Cheng Li, the Founder, President, and CEO of Ractigen, expressed excitement about this pivotal achievement: “This moment is crucial for our company, as RAG-17 is our first siRNA drug targeting the central nervous system to gain CDE approval. We look forward to advancing this therapy into clinical trials for ALS patients and are hopeful about its potential to provide substantial benefits to those with the SOD1 mutation.”

Mr. Lei Cai, an eminent ALS advocate in China who also battles the disease, shared his hopeful outlook regarding RAG-17: “I am very optimistic about RAG-17. Its innovative approach and promising early results give me great confidence in its potential. I believe this drug could offer significant hope and tangible benefits to the ALS community, particularly for those with the SOD1 mutation.”

In March 2023, RAG-17 received Orphan Drug Designation from the U.S. Food and Drug Administration and has been authorized for clinical trials in the United States. Additionally, an Investigator-Initiated Trial is currently ongoing for RAG-17, with 6 patients enrolled and treated, demonstrating encouraging preliminary safety and efficacy outcomes.

RAG-17 is a therapeutic siRNA specifically designed to inhibit the SOD1 gene in ALS patients with pathogenic mutations. RAG-17 leverages Ractigen’s proprietary SCAD delivery platform, combining siRNA with an accessory oligonucleotide to enhance its effectiveness in central nervous system tissues. 

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of May 23, 2024, there are 53 investigational drugs for the SOD1 targets, including 86 indications, 70 R&D institutions involved, with related clinical trials reaching 84, and as many as 14166 patents.

RAG-17 targets SOD1 and focusing on therapeutic areas such as Nervous System Diseases and Endocrinology and Metabolic Disease. It has reached Phase 1 of development globally and Early Phase 1 in China, with a regulatory status as an Orphan Drug. The drug's focus on addressing ALS and related conditions through its targeting of SOD1 represents a significant development in the pharmaceutical industry's efforts to address unmet medical needs in the field of bio.

图形用户界面, 文本, 应用程序

描述已自动生成

Weekly Insulin Efsitora Alfa Reduces A1C and Matches Daily Insulin Safety
Latest Hotspot
3 min read
Weekly Insulin Efsitora Alfa Reduces A1C and Matches Daily Insulin Safety
24 May 2024
With Weekly Dosing, Insulin Efsitora Alfa Achieves A1C Reduction and Matches Safety of Daily Insulin.
Read →
Iterion Begins Tegavivint Phase 1b/2a Trial for Advanced HCC Patients After Systemic Treatment Failure
Pharma Pioneer
3 min read
Iterion Begins Tegavivint Phase 1b/2a Trial for Advanced HCC Patients After Systemic Treatment Failure
24 May 2024
Biopharmaceutical firm Iterion Therapeutics has initiated a Phase 1b/2a clinical trial for its lead drug candidate, tegavivint, which is designed to inhibit Transducin beta-like protein 1 (TBL1).
Read →
Immune-Onc Initiates Global Phase 1b/2 Trial of IO-108 for Advanced Liver Cancer
Pharma Pioneer
2 min read
Immune-Onc Initiates Global Phase 1b/2 Trial of IO-108 for Advanced Liver Cancer
24 May 2024
Immune-Onc Therapeutics has entered into a clinical trial collaboration with Roche to assess the potential of IO-108 as a first-line treatment for hepatocellular carcinoma (HCC).
Read →
NextPoint Initiates Phase 1a/b Trial of NPX887 for HHLA2+ Solid Tumors
Pharma Pioneer
2 min read
NextPoint Initiates Phase 1a/b Trial of NPX887 for HHLA2+ Solid Tumors
24 May 2024
NextPoint Therapeutics has initiated a Phase 1 clinical trial for NPX887, a drug designed to target solid tumors with high expression of the HHLA2/B7-H7 antigen.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.